JLPC(SH:600513) Shang Hai Zheng Quan Bao·2025-11-17 18:51Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of Tadalafil tablets, which is expected to enhance the company's product line and market competitiveness [1][4]. Group 1: Drug Information - Tadalafil tablets are primarily used for the treatment of erectile dysfunction (2.5mg and 5mg specifications) and for erectile dysfunction combined with benign prostatic hyperplasia (only 5mg specification) [1]. - As of the announcement date, the domestic sales revenue of Tadalafil tablets in sample hospitals for 2024 is approximately 142.73 million yuan [1]. Group 2: Research and Development - The company has invested approximately 11.95 million yuan in the research and development of Tadalafil tablets (2.5mg, 5mg, 10mg, 20mg) as of the announcement date [2]. - In 2025, the company has obtained 11 product varieties, 13 production approvals, and 2 clinical approvals [3]. Group 3: Impact on the Company - The approval of the Tadalafil tablets is expected to enrich the company's product line and enhance its market competitiveness, although it is not anticipated to have a significant impact on the company's recent operating performance [4].